{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "OMDA",
  "name": "Omada Health, Inc.",
  "url": "https://frontierpicks.com/dossiers/OMDA/",
  "json_url": "https://frontierpicks.com/dossiers/OMDA.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a1",
    "n": 1
  },
  "current_thesis": "Post-print re-rating has stalled into a two-week range — $23.89 on 2026-08-21 versus the $26.78 52-week high — after Q2 (2026-08-06) beat at $87.8M revenue (+43%) and lifted the FY guide to $334–340M. The 2026-09-10 first-ever Investor Day is the next binary: GLP-1 prescribing, Flex Care and the cholesterol program, all excluded from guidance, either get a dated ramp or stay unmodelled.",
  "invalidation_trigger": "A weekly close below $22 gives back the entire post-print leg and puts price under the mid-July shelf ($23.44 on 2026-07-14, $23.70 on 2026-07-17); secondarily, the 2026-09-10 Investor Day passing without a dated contribution path for GLP-1 prescribing, Flex Care or the cholesterol program.",
  "catalyst_date": "2026-09-10",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services",
    "precision-biotech-therapeutics",
    "ai-enterprise-software"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Insider sales at Omada run under Rule 10b5-1 plans (President Shao's adopted 2026-03-13), so they are scheduled rather than discretionary signals.",
    "FY2026 guidance of $334-340M is stated as excluding material contribution from GLP-1 prescribing, Flex Care and the cholesterol program.",
    "Listed June 2025 at an IPO price of $19; the lockup has cleared. Public operating history is five quarters, limiting multi-year comparables.",
    "Hardware sits inside the revenue mix (Q1 2026: $8.5M of $78.0M), so blended gross margin is not directly comparable to pure-software peers.",
    "CEO succession is pre-announced for 2027-01-01: Wei-Li Shao in, co-founder Sean Duffy to Founder and Executive Chair.",
    "Sell-side targets span $25 (Baird, 2026-08-12) to $35 (BTIG, 2026-08-10); there is no consensus terminal value for this name."
  ],
  "body_markdown": "## Current Thesis\n\nThe binary resolved on 2026-08-06 and it resolved in the bulls' favour: Q2 2026 revenue $87.835M, +43% YoY, against $80.190M consensus; EPS $0.08 versus a $(0.01) estimate; adjusted EBITDA $11M against a $(0.2)M loss a year earlier; GAAP net income $5M, the second consecutive GAAP-positive quarter; FY2026 revenue guidance lifted to $334–340M from $322–330M, above the $327.789M the Street carried. What has changed since the 2026-08-15 note is not the fundamentals — no company filing or release has landed since — but the tape. Price closed $23.89 on 2026-08-21 against $24.04 on 2026-08-14 and a 52-week high of $26.78, so the beat-and-raise leg has spent two weeks going sideways roughly 10.8% under its high while the target raises finished landing. The narrative leg an investor is buying is unchanged: GLP-1 adoption expands, rather than obsoletes, the addressable market for the behaviour-change and coaching wrap, and Omada is now proving it with operating leverage instead of a story. The open question is the first-ever Investor Day on 2026-09-10, where the GLP-1 prescribing, Flex Care and cholesterol programs — all explicitly excluded from the $334–340M guide — either receive a dated ramp or stay unmodelled for another quarter.\n\n**The narrative is maturing.** accelerating was the right label through mid-July, when the name was still being discovered: BTIG initiated Buy $30 on 2026-07-17, Citizens raised to $27 on 2026-07-20, and the Investor Day was announced 2026-07-15. Since the print, coverage has broadened rather than deepened — twelve sell-side analysts now carry the name per stockanalysis.com as of 2026-08-21, with an average target of $28.25 — and the flow has moderated: five target actions between 2026-08-03 and 2026-08-14 produced a lower close on 2026-08-21 than the one before them. Well known, still working, thinner marginal bid. Not saturated, because the 2026-09-10 event is undelivered and the largest revenue lines in the story are not yet in any guide.\n\n## Bull Case\n\n- **Operating leverage arrived ahead of the revenue line.** Q2 2026 (2026-08-06): adjusted EBITDA $11M versus $(0.2)M in Q2 2025, GAAP gross margin 73% at a quarterly record, GAAP net income $5M. FY adjusted EBITDA is guided $21–27M.\n- **Two consecutive guidance raises.** FY2026 revenue went to $322–330M on 2026-05-07, then $334–340M on 2026-08-06. The August range cleared the $327.789M consensus outright rather than straddling it.\n- **Member growth has not hit the bear threshold.** 1.1 million total members at 2026-06-30, +45% YoY, after 1.025M and +51% at Q1-end. The prior note's deceleration marker — growth falling through roughly 40% — was not tripped.\n- **Revenue per member is not carrying the growth.** TTM revenue per total member of approximately $284 at 2026-06-30, up roughly 2% YoY (Q2 release), so the +43% top line is coming from enrolled lives rather than price. That is the cleaner variable to underwrite into the 2027 employer selling season.\n- **Financing is off the table.** $222M cash and equivalents at 2026-06-30 against a GAAP-profitable quarter. Market capitalisation of $1.46 billion on 61.22 million shares outstanding and TTM revenue of $309.76M, +47.6% (stockanalysis.com, 2026-08-21).\n- **Guidance still excludes the optionality.** GLP-1 prescribing, Flex Care and the cholesterol program contribute nothing material to the $334–340M range by management's own framing, which makes 2026-09-10 the first venue where they get quantified.\n\n## Bear Case\n\n- **The upgrade cycle is crowded and the covering houses disagree.** Barclays Overweight $25 (2026-08-03), BTIG Buy $35 (2026-08-10), Baird Neutral $25 (2026-08-12), JP Morgan Overweight $30 and Citizens Market Outperform $32 (both 2026-08-14). Baird's $25 sits about 5% above the 2026-08-21 close of $23.89; the $25-to-$35 spread is a wide disagreement on terminal value for a company with five public quarters.\n- **The tape gave the print back.** A 52-week high of $26.78 followed by closes of $24.04 on 2026-08-14 and $23.89 on 2026-08-21. Beat-and-raise news that is is a different structure than one that is, and the giveback happened while upgrades were still printing.\n- **Second-half arithmetic needs checking against the raise.** Q1 revenue was $78.0M and Q2 $87.8M; the $334–340M FY range has to be reconciled to those two figures, and a reader should work out whether the implied H2 embeds a step down from Q2's +43% growth rate before paying for continuation.\n- **Investor Day is two-sided.** A first Investor Day is where long-term frameworks get set. If the multi-year growth algorithm presented on 2026-09-10 lands below what a +44.7% three-month move implies, the event resets the model downward without any change in the business.\n- **A founder handoff sits at the top of the re-rating.** Announced 2026-08-06: Wei-Li Shao becomes CEO effective 2027-01-01, Sean Duffy moves to Founder and Executive Chair, Jeri Hilleman becomes Lead Independent Director. Pre-announced and orderly, but the transition lands inside the 2027 selling season.\n\n## Setup & Price Structure\n\n- Last completed daily close $23.89 on 2026-08-21; 52-week high $26.78; 10.8% below that high; three-month price change of +44.7%; RSI(14) at 65.1.\n- The relevant floor is the mid-July shelf that formed before the print: closes of $23.44 on 2026-07-14 and $23.70 on 2026-07-17. The 2026-08-21 close sits just above it, which means the entire post-print advance has been retraced into the pre-print base without breaking it.\n- Above, the reclaim levels are the $25.87 October-2025 pivot and then the $26.78 high. Neither has been retaken since the print.\n- RSI at 65.1 while price is 10.8% off the high says the moving averages have caught up to price during the sideways period rather than price extending away from them — the readout is consolidation, not exhaustion, though the two look identical until one resolves.\n- Crowding and positioning observables, stated as observables: twelve covering analysts with an average target of $28.25 against a $23.89 close (stockanalysis.com, 2026-08-21); five target revisions inside twelve days ending 2026-08-14; a Form 4 dated 2026-08-12 showing President Wei-Li Shao selling 8,866 shares at $25.0167 under a Rule 10b5-1 plan adopted 2026-03-13, leaving 307,372 shares held directly; 61.22 million shares outstanding, a small float for a June-2025 IPO whose lockup has cleared. No new company filing has been disclosed since 2026-08-14.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-10** — First-ever Investor Day, New York City, 1:00pm EDT, live webcast (announced 2026-07-15). The only dated company event inside the window. Long-term targets, and any quantified schedule for GLP-1 prescribing, Flex Care and the cholesterol program, land here or do not.\n- **~2026-11-05 (est.)** — Q3 2026 results, timing estimated from the 2026-05-07 and 2026-08-06 reporting cadence. Outside the 30-day window; the first hard check on the H2 path implied by the $334–340M guide.\n- **2027-01-01** — CEO transition takes effect. Commentary at the Investor Day is the earliest read on how the handoff is being staged.\n\n## What Would Change Our Mind\n\nThe structure that matters is the pre-print shelf at $23.44–$23.70 from mid-July. Losing it would mean the 2026-08-06 beat, the guidance raise and five target increases produced no durable bid, which is a statement about who is left to buy rather than about the quarter. Concretely: a weekly close below $22 gives back the entire post-print leg and puts price under that shelf. A second, independent break is the 2026-09-10 Investor Day passing without a dated contribution path for GLP-1 prescribing, Flex Care or the cholesterol program — the excluded lines are the reason the name carries a growth multiple, and an Investor Day that leaves them qualitative converts the story back to the guided $334–340M business. On the other side, a weekly close above $25.87 that holds would say the consolidation resolved upward and the label stays maturing rather than rolling toward saturated. A Q3 print (est. ~2026-11-05) implying a sequential decline against Q2's $87.8M would break the continuation case regardless of where price sits.\n\n## Correlation Notes\n\n- **GLP-1 complex.** Omada trades as a second-order expression of GLP-1 adoption; sentiment shifts in the obesity-drug names and in payer coverage decisions for GLP-1s propagate here without touching Omada's own numbers. The company's framing is that prescribing volume expands the wrap-around market; a payer pullback on GLP-1 coverage would test that directly.\n- **Digital-health and virtual-care cohort.** Multiple compression across employer-benefit and virtual-care peers has historically moved this group together irrespective of individual execution, and Omada's five-quarter public history gives it no separate valuation anchor.\n- **Employer plan-design cycle.** Revenue is contracted through employers and health plans, so the calendar-Q3/Q4 selling season for 2027 is the shared variable across the cohort. Commentary on it at the 2026-09-10 event or the Q3 call is the check.\n- **Small-float mechanics.** 61.22 million shares outstanding (stockanalysis.com, 2026-08-21) against a $1.46 billion market capitalisation means index-flow and single-block events move price disproportionately relative to news flow.",
  "first_seen": "2026-07-14",
  "last_analyzed": "2026-08-23T14:51:47+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}